Prognosis in patients with hepatocellular carcinoma correlates to mutations of p53 and/or hMSH2 genes

European Journal of Cancer

Volumn 43, Issue 6, 2007, Pages 1092-1100

  Yano, Masatsugu ^a   Hamatani, Kiyohiro ^b   Eguchi, Hidetaka ^b   Hirai, Yuko ^b   MacPhee, Donald G ^b   Sugino, Keizo ^a   Dohi, Kiyohiko ^a   Itamoto, Toshiyuki ^c   Asahara, Toshimasa ^c  

^a TSUCHIYA GENERAL HOSPITAL   (Japan)

^b RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; hMSH2 gene; Intrahepatic metastasis; Multicentric occurrence; p53 gene

Indexed keywords

PROTEIN MSH2; PROTEIN P53;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; HMSH2 GENE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; P53 GENE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE;

AGED; ANALYSIS OF VARIANCE; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; EXONS; FEMALE; GENES, P53; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; MUTS HOMOLOG 2 PROTEIN; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS;

EID: 33947588546     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.01.032     Document Type: Article

References (33)

1. Suriawinata A., and Xu R. An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis 24 (2004) 77-88
2. Sun M., Eshleman J.R., Ferrell L.D., et al. An early lelsion in hepatic carcinogenesis: Loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. Hepatology 33 (2001) 1415-1424
3. Yeh S.H., Chen P.J., Shau W.Y., et al. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma. Gastroenterology 121 (2001) 699-709
4. Yano M., Asahara T., Dohi K., Mizuno T., Iwamoto K.S., and Seyama T. Close correlation between a p53 or hMSH2 gene mutation in the tumor and survival of hepatocellular carcinoma patients. Int J Oncol 14 (1999) 447-451
5. Katiya S., Dash B.C., Thakur V., Guptan R.C., Sarin S.K., and Das B.C. P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India. Cancer 88 (2000) 1565-1573
6. Wang L., Bani-Hani A., Montoya D., et al. hMLH1 and hMSH2 expression in human hepatocellular carcinoma. Int J Oncol 19 (2001) 567-570
7. Hussein M.R. Alterations of p53, Bcl-2, and hMSH2 protein expression in the cirrhotic, macroregenerative, dysplastic nodules and hepatocellular carcinomas in upper Egypt. Liver Int 24 (2004) 552-560
8. Salvucci M., Lemoine A., Saffroy R., et al. Microsatellite instability in European hepatocellular carcinoma. Oncogene 18 (1999) 181-187
9. Macdonald G.A., Greenson J.K., Saito K., Cherian S.P., Appelman H.D., and Boland C.R. Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis. Hepatology 28 (1998) 90-97
10. Zekri A.R., Sabry G.M., Bahnassy A.A., Shalaby K.A., Abdel-Wahabh S.A., and Zakaria S. Mismatch repair genes (hMLH1, hPMS1, hPMS2, GTBP/hMSH6, hMSH2) in the pathogenesis of hepatocellular carcinoma. World J Gastroenterol 11 (2005) 3020-3026
11. Shimada M., Takenaka K., Gion T., et al. Prognosis of recurrent hepatocellular carcinoma: A 10-year surgical experience in Japan. Gastroenterology 111 (1996) 720-726
12. Sugimachi K., Maehara S., Tanaka S., Shimada M., and Sugimachi K. Repeat hepatectomy is the most useful treatment for recurrent hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 8 (2001) 410-416
13. Kumada T., Nakano S., Takeda I., et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 25 (1997) 87-92
14. Shimada M., Hamatsu T., Yamashita Y., et al. Characteristics of multicentric hepatocellular carcinomas: Comparison with intrahepatic metastasis. World J. Surg. 25 (2001) 991-995
15. Hussein M.R., Hassan M., and Wood G.S. Morphological changes and apoptosis in radial growth phase melanoma cell lines following ultraviolet-B irradiation. Am J Dermatopathol 25 (2003) 466-472
16. Karachristos A., Liloglou T., Field J.K., Deligiorgi E., Kouskouni E., and Spandidos D.A. Microsatellite instability and p53 mutations in hepatocellular carcinoma. Mol Cell Biol Res Commun 2 (1999) 155-161
17. Scherer S.J., Welter C., Zang K.D., and Dooley S. Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2. Biochem Biophys Res Commun 221 (1996) 722-728
18. Warnick C.T., Dabbas B., Ford C.D., and Strait K.A. Identification of a p53 response element in the promoter region of the hMSH2 gene required for expression in A2780 ovarian cancer cells. J Biol Chem 276 (2001) 27363-27370
19. Edmondson H.A., and Steiner P.E. Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies. Cancer 7 (1954) 462-503
20. Orita M., Suzuki Y., Sekiya T., and Hayashi K. Rapid and sensitive detection of point mutation and DNA polymorphisms using the polymerase chain reaction. Genomics 5 (1989) 874-879
21. Oda T., Tsuda H., Scarpa A., Skakmoto M., and Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 52 (1992) 6358-6364
22. Kobayashi K., Matsushima M., Koi S., et al. Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic endometrial carcinomas with microsatellite instability. Jpn J Cancer Res 87 (1996) 141-145
23. Bhattacharyya N.P., Skandalis A., Ganesh A., Groden J., and Meuth M. Mutator phenotypes in human colorectal carcinoma cell lines. Proc Natl Acad Sci USA 91 (1994) 6319-6323
24. Hanford M.G., Rushton B.C., Gowen L.C., and Farber R.A. Microsatellite mutation rates in cancer cell lines deficient or proficient in mismatch repair. Oncogene 16 (1998) 2389-2393
25. Wind N., Dekker M., Berns A., Radman M., and Riele H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation torelance, hyperrecombination, and predisposition to cancer. Cell 82 (1995) 321-330
26. Surtees J.A., Argueso J.L., and Alani E. Mismatch repair proteins: key regulators of genetic recombination. Cytogenet Genome Res 107 (2004) 146-159
27. Chan K.T., and Lung M.L. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother Pharmacol 53 (2004) 519-526
28. Rellecke P., Kuchelmeister K., Schachenmayr W., and Schlegel J. Mismatch repair protein hMSH2 in primary drug resistance in in vitro human malignant gliomas. J Neurosurg 101 (2004) 653-658
29. Lin X., and Howell S.B. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Ther 5 (2006) 1239-1247
30. Liver Cancer Study Group of Japan. Classification of Primary Liver Cancer. Tokyo: Kanehara; 1997, p.38.
31. Yamamoto T., Kajino K., Kudo M., Sasaki Y., Arakawa Y., and Hino O. Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA. Hepatology 29 (1999) 1446-1452
32. Ng I.O., Guan X.Y., Poon R.T., Fan S.T., and Lee J.M. Determination of the molecular relationship between multiple tumor nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol 199 (2003) 345-353
33. Morimoto O., Nagano H., Sakon M., et al. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol 39 (2003) 215-221